Pfizer's Oncology Portfolio Drives Sales Growth, Potential Future Growth Opportunities Ahead

Pfizer's oncology sales grew 9% in H1 2025, driven by drugs like Xtandi, Lorbrena, Braftovi/Mektovi, and Padcev. The addition of Seagen in 2023 strengthened its position in oncology, with acquired products contributing meaningfully to revenues. Pfizer's diversified portfolio of oncology drugs should support top-line growth in H2 2025.

Pfizer's (PFE) oncology division has shown remarkable resilience and growth in the first half of 2025, with sales increasing by 9% compared to the same period last year. This performance is driven by a diversified portfolio of oncology drugs, including Xtandi, Lorbrena, Braftovi/Mektovi, and Padcev, which have seen significant revenue growth.

The addition of Seagen in 2023 has further bolstered Pfizer's oncology position. The acquired products, including four antibody-drug conjugates (ADCs) — Adcetris, Padcev, Tukysa, and Tivdak — have contributed meaningfully to the company's revenues in 2024 and the first half of 2025. Padcev, in particular, saw a 38% increase in sales, driven by strong demand trends. Additionally, Pfizer has ventured into the oncology biosimilars space, with revenues from these products rising by 27% year over year in the second quarter.

Pfizer's oncology portfolio is well-positioned to support top-line growth in the second half of 2025. The company has several late-stage development candidates, such as sasanlimab, vepdegestrant, and sigvotatug vedotin, which are expected to enter the market in the coming years. By 2030, Pfizer aims to have eight or more blockbuster oncology medicines in its portfolio, further solidifying its leadership in the oncology market.

In July 2025, Pfizer closed a global ex-China in-licensing agreement, which will further enhance its oncology pipeline and revenue streams. This strategic move underscores the company's commitment to innovation and growth in the oncology space.

References:
[1] https://www.crispidea.com/pharma-stocks-2025-pfizer-novartis-astrazeneca/?srsltid=AfmBOooWVcA1sPDzZbcep60YNbnHNZytTBViaBO7gsYbds2NF_mamAsf
[2] https://www.nasdaq.com/articles/pfizer-oncology-drugs-drive-sales-q2-will-trend-continue